Bristol Myers Squibb’s Opdivo receives EC approval for second-line treatment of ESCC
Bristol Myers Squibb (BMS) has achieved a significant milestone with the approval of its immunotherapy drug, Opdivo (nivolumab),…
Merck acquisition of OncoImmune: A strategic move to strengthen COVID-19 treatment pipeline
In a significant acquisition aimed at enhancing its COVID-19 therapeutic offerings, pharmaceutical giant Merck has entered into an…
FDA accepts SB11 BLA for review: A step towards affordable treatment for retinal vascular disorders
The United States Food and Drug Administration (FDA) has recently accepted the biologics license application (BLA) for SB11,…
Bristol Myers Squibb completes $13.1bn acquisition of MyoKardia: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb has successfully completed its acquisition of MyoKardia, a clinical-stage biopharmaceutical company based in California. The…
ExeGi Pharma’s EXE-346 receives FDA orphan drug designation for pouchitis treatment
ExeGi Pharma, a biotechnology company headquartered in Rockville, Maryland, has announced that its live biotherapeutic product (LBP), EXE-346,…
Olema Oncology partners with Pfizer for advanced breast cancer clinical trial
Olema Oncology, a leading California-based biopharmaceutical company focused on women’s cancer therapies, has entered a strategic partnership with…
Adagio Medical raises $42.5m in Series E to transform cardiac ablation treatment
Adagio Medical, a California-based medical device company specializing in innovative treatments for atrial fibrillation (AF) and ventricular tachycardia…
FDA grants emergency use authorization for Bamlanivimab to treat Covid-19
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for bamlanivimab (LY-CoV555), a neutralizing…
Pfizer and BioNTech’s Covid-19 vaccine candidate shows over 90% effectiveness in Phase 3 Trial
Pfizer and BioNTech have announced a groundbreaking update in their efforts to combat the Covid-19 pandemic. Their BNT162b2…
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the…